Meridiano

Add Article

No Image Available

Article Details

Title

Article: Capital injection: China backs AI drug makers in self-reliance drive

Impact Score

6 / 10

AI Summary (Processed Content)

The Chinese government is directing significant investment into domestic AI-driven pharmaceutical companies as part of a broader push for technological self-reliance. A key example is Hangzhou-based METiS TechBio, which secured substantial state-linked funding and has developed China's first AI-designed drug candidate to reach Phase III clinical trials.

The company plans to seek regulatory approval in China this year and is considering a Hong Kong IPO. This activity highlights Beijing's strategic effort to build an independent biotech ecosystem by financing innovative firms in the sector.

The main topics covered are: Chinese government investment in AI drug discovery, the progress of a specific company (METiS TechBio), and the national drive for biotech self-reliance.

Original URL

https://www.scmp.com/business/banking-finance/article/3343151/capital-injection-china-backs-ai-drug-makers-self-reliance-drive?utm_source=rss_feed

Source Feed

Big Tech - South China Morning Post

Published Date

2026-02-11 06:00

Fetched Date

2026-03-04 14:30

Processed Date

2026-03-04 15:19

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

Capital injection: China backs AI drug makers in self-reliance drive
A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem
Hangzhou-based METiS TechBio, founded in 2020, raised 400 million yuan (US$57.9 million) in series D financing in August last year, led by the Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund – both government-linked vehicles – according to the company’s website.
Using a proprietary AI platform focused on optimising drug delivery, the company has developed MTS-004, an oral treatment for neurological disorders that has completed Phase III trials, making it China’s first AI-designed drug candidate to reach that stage.
The company plans to seek regulatory approval in China this year.
In earlier funding rounds totalling about US$150 million in 2022, METiS attracted a broad mix of domestic investors, including state-linked insurers PICC Capital and China Life Private Equity, as well as venture firm HongShan, formerly known as Sequoia China before splitting from its US parent in 2023.
METiS is also considering a Hong Kong initial public offering that could raise about US$200 million, according to a Bloomberg report published last May.